MetabolicResearch Market

AOD-9604

A modified fragment of human growth hormone discussed in weight-management and fat-metabolism circles, but not approved as an FDA drug.

MetabolicWeight ManagementhGH Fragment

Also referenced as: Advanced Obesity Drug-9604

Price compare
152 tracked offers across 152 vendors · 16 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $3.60/mg
From
$3.60/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$3.60/mg
Market median$9.00/mg
Current coverage69 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when AOD-9604 crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence160 certificate records mentioning this compound or product name93 provider-linked · 130 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Metabolic / incretin research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases
1

Advanced Obesity Drug-9604

Signal depth
Low

No FDA label signal · 0 trials · 12 PubMed results

Preclinical
Research evidence

Current evidence for AOD-9604 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

AOD-9604 has no clinical trials that name it and 12 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Emerging
PubMed · 3 citationsAOD-9604 Metabolic.Inpharma WeeklyThe orally active peptide AOD 9604* may aid weight reduction in obese subjects,Inpharma WeeklyThe anti-obesity drug AOD-9604* has demonstrated favourable safety and tolerability in a phase II clinical trial.Journal ArticleSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Journal ArticleTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal ArticleHuman Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What AOD-9604 is

AOD-9604 is a modified fragment of human growth hormone built around amino acids 176-191. It is usually discussed as a body-composition or weight-management compound rather than as a classic growth-hormone replacement medicine.

Why people track it

The compound shows up often in peptide conversations because it is framed as a metabolic or lipolytic fragment rather than a full GH analog. That distinction is part of the marketing story around it, but it is not the same thing as having an FDA-approved obesity indication.

Regulatory context

AOD-9604 is not an FDA-approved drug in the United States. On this site it belongs in the research-market bucket, not the approved-medicine bucket.

Practical reading note

If you see aggressive claims around AOD-9604, the useful questions are:

  • what jurisdiction is being referenced
  • whether the seller is describing a research product or a regulated medicine
  • and whether any claimed outcome is coming from robust human evidence or from broader peptide-marketing language